Drugs

, Volume 72, Supplement 1, pp 3–10

Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation

  • Tony S. K. Mok
  • Manolo D’arcangelo
  • Raffaele Califano
Review Article

DOI: 10.2165/1163014-S0-000000000-00000

Cite this article as:
Mok, T.S.K., D’arcangelo, M. & Califano, R. Drugs (2012) 72(Suppl 1): 3. doi:10.2165/1163014-S0-000000000-00000

Abstract

The epidermal growth factor receptor (EGFR) mutation is the first recognized molecular target in non-small cell lung cancer that makes personalized therapy feasible. This molecular alteration has been demonstrated to be more frequent in Asians, non-smokers and patients with adenocarcinoma histology. Several retrospective and subgroup analyses of phase III trials have shown the single agent, erlotinib, to be associated with higher response rates and longer progression-free survival in patients harbouring an EGFR mutation. Two prospective randomized phase III studies from China and Europe have confirmed the role of first-line erlotinib in patients with the mutations. Erlotinib has also been evaluated in combination with chemotherapy in either a concurrent or intercalated regimen. Earlier trials were limited by little information on the EGFR mutational status of the enrolled patients, and an ongoing phase III trial with translational biomarker analysis will provide more comprehensive data on the combination.

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Tony S. K. Mok
    • 1
  • Manolo D’arcangelo
    • 2
  • Raffaele Califano
    • 3
  1. 1.State Key Laboratory of Southern ChinaThe Chinese University of Hong Kong, Sir YK Pau Cancer Center, Prince of Wales HospitalHong KongChina
  2. 2.Istituto Toscano Tumori, Medical OncologyLivorno Civil HospitalLivornoItaly
  3. 3.Department of Medical OncologyThe Christie NHS Foundation TrustManchesterUK
  4. 4.Department of Clinical OncologyThe Chinese University of Hong Kong, Prince of Wales HospitalShatin, New Territories, Hong KongChina

Personalised recommendations